Description
Avoid concurrent use with opioids, alcohol, barbiturates, or other CNS depressants — may cause profound sedation and respiratory depression.
Potent CYP3A inhibitors/inducers alter alprazolam exposure — adjust therapy per clinical guidance.
Risk of tolerance, dependence, and severe withdrawal with abrupt cessation after prolonged use; taper per clinical protocol.
Counterfeit tablets and diverted products pose serious overdose risk; verify authenticity via pharmacy supply chain and CoA where applicable.
Quality control checklist (required before dispensing / institutional acceptance):
Valid prescriber prescription on file.
Certificate of Analysis (CoA) confirming identity and potency from licensed supplier.
In-house or partner laboratory confirmation (HPLC/LC-MS) when provenance uncertain.
Chemical-safety SOP and patient counseling materials on file.
Regulatory / compliance note: Dispense only through licensed pharmacy channels; maintain records for controlled-substance regulations and audit. Not for research procurement without institutional approvals and appropriate controlled-substance licensing.
Reviews
There are no reviews yet.